{"id":993249,"date":"2026-08-11T06:35:21","date_gmt":"2026-08-11T10:35:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/"},"modified":"2026-08-11T06:35:21","modified_gmt":"2026-08-11T10:35:21","slug":"immunic-inc-reports-second-quarter-2026-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-inc-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/","title":{"rendered":"Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n \u2013 Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness \u2013<\/i>\n <\/p>\n

\n \u2013 Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 \u2013<\/i>\n <\/p>\n

\n \u2013 Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year \u2013<\/i>\n <\/p>\n

\n NEW YORK<\/span>, Aug. 11, 2026<\/span> \/PRNewswire\/ — Immunic<\/b>, Inc.<\/b><\/a>\u00a0(Nasdaq: IMUX),\u00a0a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.<\/p>\n

“During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic,” said Erik Lundgren, Chief Executive Officer of Immunic. “As we prepare for the next stage of Immunic’s growth, we have continued to strengthen our board and team with world-class multiple sclerosis (MS) experts whose extensive development, medical, regulatory and commercialization expertise will be instrumental as we execute on our clinical strategy and prepare for the potential regulatory filings and commercialization of vidofludimus calcium (IMU-838). Following the successful closing of our oversubscribed private placement financing earlier this year, we are well capitalized to execute on our key strategic priorities. We believe the milestones ahead position Immunic for a significant near-term value inflection for vidofludimus calcium in relapsing MS, while continuing to unlock the substantial long-term opportunity across the broader progressive MS patient population.”<\/p>\n

Jason Tardio, President and Chief Operating Officer of Immunic, commented, “We remain highly encouraged by the consistent and differentiated profile of vidofludimus calcium, supported by additional data from our Phase 2 CALLIPER trial in progressive MS presented at this year’s CMSC Annual Meeting, including favorable safety, tolerability, patient-reported, and exploratory efficacy data. Taken together, these findings reinforce our confidence in the potential of vidofludimus calcium to offer a differentiated benefit\/risk profile through its novel dual mechanism of action, combining Nurr1 activation with selective DHODH inhibition. We believe this approach has the potential to deliver meaningful efficacy while maintaining the favorable safety and tolerability profile observed to date, positioning vidofludimus calcium as a potentially important new oral treatment option for people living with MS.”<\/p>\n

“Our Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS remain on track to report top-line data by the end of 2026,” added Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic. “With regulatory alignment and precedent surrounding the time to first relapse primary endpoint, the path to regulatory submission upon positive trial results is clear. In parallel, we are preparing to initiate our Phase 3 progressive MS trial later this year, reinforcing our commitment to evaluating the potential of vidofludimus calcium for anyone living with MS.”<\/p>\n

\n Second Quarter 2026 and Subsequent Highlights<\/b>\n <\/p>\n